Highlights from the 2008 Gastrointestinal Cancers Symposium

European Journal of Cancer Care

Volumn 18, Issue 1, 2009, Pages 10-17

  Aprile, G ^a   Sobrero, A ^b  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Chemotherapy; Colorectal cancer; Gastric cancer; Pancreatic cancer; Phase III studies; Predictive factors; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; GASTROINTESTINAL TUMOR; HUMAN; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GASTROINTESTINAL NEOPLASMS; HUMANS;

EID: 58149287920     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2008.01022.x     Document Type: Conference Paper

References (47)

1. Abou-Alfa G.K., Johnson P., Knox J., Davidenko I., Lacava J., Leung T., Mori A., Le Berre M., Voliotis D. Saltz L.B. (2008) Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S + D) versus placebo plus doxorubicin (P + D) in aptients (pts) with advanced hepatocellular carcinoma (AHCC). 2008 Gastrointestinal Cancers Symposium Proceedings abstract 128.
2. Allum W.H., Fogarty P.J., Stenning S.P. Langley L.E. (2008) Long term results of the MRC OE02 randomized trial of surgery with or without preoperative chemotherapy in resectable esophageal cancer. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 9.
3. Amado R.G., Wolf D., Freeman D., Peeters M., Van Cutsem E., Siena S., Suggs S., Devercelli G., Woolley M. Chang D. (2008) Panitumumab (pmab) efficacy and patient-reported outcomes (PRO) im metastatic colorectal cancer (mCRC) patients (pts) with wild-type (WT) KRAS tumor status. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 278.
4. American College of Physicians (2008) Achieving a high-performance health care system with universal access: what the United States can learn from other Countries. Annals of Internal Medicine 148, 55 75.
5. Anandasabapathy S., Jhamb J., Davila M., Wei C., Morris J. Bresalier R. (2007) Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia. Cancer 109, 668 674.
6. Ando N., Kato H., Shinoda M., Ozawa S., Shimizu H., Nakamura T., Yabuzaki Y., Aoyama N., Kurita A. Fukuda H. (2008) A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for localized squamous cell carcinoma of the thoracic esophagus (JCOG 9907). 2008 Gastrointestinal Cancers Symposium Proceedings abstract 10.
7. Artinyan A., Hellan M., Mojica-Manosa P., Chen Y.J., Pezner R., Ellenhom J.D. Kim J. (2008) Improved survival with adjuvant external-beam radiation therapy in lymph node-negative pancreatic cancer: a United States population-based assessment. Cancer 112, 34 42.
8. Benvenuti S., Sartore-Bianchi A., Dinicolantonio F., Zanon C., Moroni M., Veronese S., Siena S. Bardelli A. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Research 67, 2643 2648.
9. Berlin J.D. (2007) Adjuvant therapy for pancreatic cancer: to treat or not to treat? Oncology 21, 712 718.
10. Blackstein M., Huang X., Demetri G.D., Casali P.G., Garrett C.R., Schöffski P., Shah M.H., Verweij J., Baum C.M. DePrimo S.E. (2008) Evaluation of soluble KIT as a potential surrogate marker for TTP in patients with advanced GIST receiving sunitinib. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 19.
11. Chung K.J., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., Hamilton A., Pan D., Schrag D., Schwartz L., Klimstra D.S., Fridman D., Kelsen D.P. Saltz L.B. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. Journal of Clinical Oncology 23, 1803 1810.
12. DeMatteo R.P., Owzar K., Antonescu C.R., Maki R.G., Demetri G.D., McCarter M., von Mehren M., Pisters P.W., Brennan M.F. Ballman K.V. (2008) Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the US Intergroup phase II trial ACOSOG Z900. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 8.
13. Demetri G.D., von Meheren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D. Joensuu H. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine 347, 472 480.
14. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., McArthur G., Judson I.R., Heinrich M.C., Morgan J.A., Desai J., Fletcher C.D., George S., Bello C.L., Huang X., Baum C.M. Casali P.G. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329 1338.
15. Demetri G.D., Wang Y., Wehrle E., Blanke C.D., Joensuu H. von Meheren M. (2008) Correlation of imatinib plasma level with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST). 2008 Gastrointestinal Cancers Symposium Proceedings abstract 3.
16. Gamelin L., Boisdron-Celle M., Delva R., Guerin-Mayer V., Ifrah N., Morel A. Gamelin E. (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusion: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clinical Cancer Research 10, 4055 4061.
17. Getzenberg R.H., Schoen R.E., Sokoll L., Chan D., Magheli A. Leman E.S. (2008) Initial evaluation of colon cancer-specific antigen-2 (CCSA-2) as a serum marker for colorectal cancer. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 276.
18. Halpern M.T. Pavluck A.L. (2008) Association between insurance status and stage at diagnosis for patients with colorectal cancer. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 275.
19. Hecht J.R., Mitchell E.P., Chidiac T., Scroggin C., Hagenstad C., Spigel D., Marshall J.L., Cohn A., Shahin S. Griffin T. (2008a) An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). 2008 Gastrointestinal Cancers Symposium Proceedings, abstract 273.
20. Hecht J.R., Mitchell E.P., Chidiac T., Scroggin C., Hagenstad C., Spigel D., Marshall J.L., Cohn A., Suzuki S. Griffin T. (2008b) Interim results from PACCE: irinotecan (iri)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) for metastatic colorectal cancer (mCRC). 2008 Gastrointestinal Cancers Symposium Proceedings, abstract 279.
21. Hochster H.S., Grothey A., Shpilsky A. Childs B.H. (2008) Effect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on response to FOLFOX + bevacizumab (BEV) in the CONcePT trial. 2008 Gastrointestinal Cancers Symposium Proceedings, abstract 280.
22. Hoskins J.M., Goldberg R.M., Qu P., Ibrahim J.G. MacLeod H.L. (2007) UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. Journal of the National Cancer Institute 99, 1290 1295.
23. Hsu C.C., Herman J.M., Corsini M.M., Winter J.M., Callister M.D., Cameron J.L., Pawlik T.M., Schulick R.D., Swartz M.J., Gunderson L.L. Miller R.C. (2008) Benefit of adjuvant chemoradiation therapy for pancreatic adenocarcinoma: the John Hopkins Hospital-Mayo Clinic collaborative study of 1045 patients. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 124.
24. Imamura H., Iishi H., Tsuburaya A., Hatake K., Imamoto H., Esaki T., Kato M., Furukawa H., Hamada C. Sakata Y. (2008) Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). 2008 Gastrointestinal Cancers Symposium Proceedings abstract 5.
25. Italiano A., Follana P., Caroli F.X., Badetti J.L., Benchimol D., Garnier G., Gugenheim J., Haudebourg J., Keslair F., Lesbats G., Liedo G., Roussel J.F., Pedeutour F. Francois E. (2008) Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Annals of Surgical Oncology 15, 649 654.
26. Jankowski J., Barr H., Love S., Attwood S., Harrison R., Watson P. Caestecker J.S. (2008) Aspirin esomeprazol chemoprevention. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 14.
27. Javle M.M., Okazaki T., Wolff R.A., Varadhachary G., Ho L., Crane C.H., San Miguel A., Evans D.B., Abruzzese J.L. Li D. (2008) Combined effect of single nucleotide plymorphisms (SNPs) of gemcitabine metabolic genes on pancreatic survival and drug toxicity. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 126.
28. Kindler H.L., Niedzwiecki D., Hollis D., Oraefo E., Schrag D., Hurwitz H., McLeod H.L., Mulcahy M.F., Schilsky R.L. Goldberg R.M. (2007) A double-blind, placebo-controlled, phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients with advanced pancreatic cancer (APC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). ASCO Annual Meeting Proceedings Part I. Journal of Clinical Oncology 25 (Suppl. 4508.
29. Koizumi W., Kurihara M., Nakano S. Hasegawa K. (2000) Phase II study of S-1, a novel oral derivate of 5-Fluorouracil, in advanced gastric cancer. Oncology 58, 191 197.
30. Kolligs F.T., Stieber P., Nagel D., Schaefer C., Becker C., Geisbuesch S., Lottes A., Reiser M.F., Goke B. Graser A. (2008) A prospective comparison of colonoscopy, signmoidoscopy, CT colonography, and stool tests in an average risk population. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 282.
31. Llouvet J., Ricci S., Mazzaferro V., Hilgard P., Raoul J., Zeuzem S., Poulin-Costello M., Moscovici M. Voliotis D. (2007) Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma. ASCO Annual Meeting Proceedings Part II. Journal of Clinical Oncology 25 (Suppl. LBA1.
32. Medical Research Council Oesophageal Cancer Working Group (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359, 1727 1733.
33. Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D.J. B?chler M.W. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. The New England Journal of Medicine 350, 1200 1210.
34. Nimeiri H.S., Maki R.G., Kasza K., D'Adamo D., Chow W., Dy P., Polite B., Jin J., Vokes E.E. Kindler H.L. (2008) Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 7.
35. Reeder C.E. Gordon D. (2006) Managing oncology costs. The American Journal of Managed Care 12, S3 S16.
36. Roth A.D., Yan P., Dietrich D., Fiocca R., Bodoky G., Labianca R., Cunningham D., Van Cutsem E., Bosman F. Tejpar S. (2008) Does UGT1A1*28 homozygousity predict for severe toxicity in patients treated with 5-fluorouracil (5-FU)-irinotecan (IRI)? Results of the PETACC 3-EORTC 40993-SAKK 60/00 trial comparing IRI/5-FU/folinic acid (FA) in stage II-III colon cancer. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 277.
37. Sakuramoto S., Sasako M., Yamaguchi T., Kinoshita T., Fujii M., Nashimoto A., Furukawa H., Nakajima T., Ohashi Y., Imamura H., Higashino M., Yamamura Y., Kurita A. Arai K. (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. The New England Journal of Medicine 357, 1810 1820.
38. Salgado J., Zabalegui N., Gil C., Monreal I., Rodriguez J. Garcia-Foncillas J. (2007) Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncology Reports 17, 325 328.
39. Seeff L.C., Richards T.B., Shapiro J.A., Nadel M.N., Manninen D.L., Given L.S., Dong F.B., Winges L.D. McKenna M.T. (2004) How many endoscopies are performed for colorectal cancer screening? Results from CDC's survey of endoscopic capacity. Gastroenterology 127, 1670 1677.
40. Small W., Mulchay M.F., Benson A., Gold S., Rademaker F., Bentrem D. Talamonti M. (2008) A phase II trial of weekly gemcitabine and bevacizumab in combination with abdominal radiation therapy in patients with localized pancreatic cancer. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 131.
41. Tournigand C., Cervantes A., Figer A., Lledo G., Flesch M., Buyse M., Mineur L., Carola E., Etienne P.L., Rivera F., Chirivella I., Perez-Staub N., Louvet C., André T., Tabah-Fisch I. De Gramont A. (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. Journal of Clinical Oncology 24, 394 400.
42. Twelves C., Wong A., Nowacki M.P., Abt M., Burris H., 3rd., Carrato A., Cassidy J., Cervantes A., Fagerberg J., Georgoulias V., Husseini F., Jodrell D., Korelewski P., Kröning H., Maroun J., Marschner N., McKendrick J., Pawlicki M., Rosso R., Schüller J., Seitz J.F., Stabuc B., Tujakowski J., Van Hazel G., Zaluski J. Scheithauer W. (2005) Capecitabine as adjuvant treatment for stage III colon cancer. The New England Journal of Medicine 352, 2696 2704.
43. Twelves C., Scheithauer W., McKendrick J., Nowacki M., Seitz J., Van Hazel G., Wong A., Diaz-Rubio E., Gilberg F. Cassidy J. (2008) Capecitabine versus 5-FU/LV in stage III colon cancer: updated 5-year efficacy data from X-ACT trial and preliminary analysis of relationship between hand-foot syndrome (HFS) and efficacy. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 274.
44. Van Cutsem E., Labianca R., Hossfeld D., Bodoky G., Roth A., Aranda E., Nordlinger B., Assadourian S., Wang K. Cunningham D. (2005) Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). 2005 ASCO Annual Meeting Proceedings. Journal of Clinical Oncology, 23, 8.
45. Van Cutsem E., Peeters M., Siena S., Humblet J., Hendlisz A., Neyns B., Canon J.L., Van Laethem J.L., Maurel J., Richardson G., Wolf M. Amado R. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology 25, 1658 1664.
46. Varadhachary G.R., Wolff R.A., Crane C.H., Lee J.E., Abdalla E.K., Lee J.E., Pisters P.W., Ho L., Abruzzese J.L. Evans D.B. (2008) Preoperative gemcitabine (gem) plus bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 130.
47. Wolfsen H.C., Crook J., Krishna M., Achem S., DeVault K., Bouras E., Loeb D., Stark M., Woodward T. Wallace M.B. (2008) Prospective controlled tandem endoscopy study of narrow band imaging for the detection of dysplasia in Barrett's esophagus. 2008 Gastrointestinal Cancers Symposium Proceedings abstract 1.